# Bazedoxifene plus conjugated estrogens for breast risk biomarkers

Source: https://onco.cc/trials/nct04821141/  
OnCo record `nct04821141` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study compares bazedoxifene plus conjugated estrogens with a waiting-list group. It measures breast cancer risk markers and menopausal symptoms, rather than treating an existing breast cancer.

## Summary

This study compares bazedoxifene plus conjugated estrogens with a waiting-list group. It measures breast cancer risk markers and menopausal symptoms, rather than treating an existing breast cancer.

Interventional study registered as NCT04821141, sponsored by University of Kansas Medical Center. Registry phase: 2. Registry enrollment is 120 participants (estimated). Registry status checked October 10, 2026: active not recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-10
- Also known as: Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens
- Tags: ucsf-breast-coverage; interventional
- Registry id: NCT04821141
- Phase: 2
- Setting: Women at increased breast cancer risk with menopausal symptoms
- Sponsor: University of Kansas Medical Center

## Sources

- ClinicalTrials.gov NCT04821141: https://clinicaltrials.gov/study/NCT04821141
- UCSF study listing and local availability: https://clinicaltrials.ucsf.edu/trial/NCT04821141

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)

---
JSON: https://onco.cc/api/v1/entities/nct04821141.json